Abbott Sees Absorb Bioresorbable Implant As Stent Market Game Changer
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm announced CE mark clearance Jan. 10, making Absorb the first drug-eluting bioresorbable vascular scaffold available to treat coronary artery disease. Abbott expects to submit a PMA by 2015.